Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
izalontamab brengitecan + ivonescimab
- Development stage
- Unknown
- Lead developer
- SystImmune
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Yizekang + ivonescimab is an investigational, chemotherapy-free combination regimen consisting of two first-in-class bispecific biologics: izalontamab brengitecan (Yizekang, BL-B01D1), an EGFRxHER3-targeting bispecific antibody-drug conjugate (ADC), and ivonescimab (YiDaFang, AK112), a PD-1xVEGF-targeting bispecific antibody. Izalontamab brengitecan consists of a humanized bispecific antibody targeting EGFR and HER3 conjugated to a novel topoisomerase I inhibitor payload (Ed-04) via a cleavable linker, designed to simultaneously block EGFR/HER3 oncogenic signaling and deliver potent cytotoxicity directly to tumor cells. Ivonescimab combines immune checkpoint inhibition (PD-1 blockade) with anti-angiogenesis (VEGF inhibition) to restore T-cell activity and normalize tumor vasculature. This combination is being evaluated in Phase II/III clinical trials, including the PANKU-Lung05 and PANKU-Lung06 studies, as a first-line treatment for patients with locally advanced or metastatic squamous and non-squamous non-small cell lung cancer (NSCLC).
- Brand names
- Yizekang + YiDaFang
- Other names
- iza-bren + ivonescimabizalontamab brengitecan + ivonescimabluncotanilontimab + ivonescimablunkangyilongtuomab + ivonescimabYizekang + ivonescimab
02
Targets
EGFR (Epidermal growth factor receptor)ERBB3 (Erb-b2 receptor tyrosine kinase 3)PDCD1 (Programmed cell death protein 1 receptor)VEGFA (Vascular endothelial growth factor A)
Beyond the preview
Go deeper on izalontamab brengitecan + ivonescimab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on izalontamab brengitecan + ivonescimab.